The product is a first in class unmodified
antisense oligodeoxynucleotide that inhibits a cell membrane hemichannel forming protein, connexin43 (Cx43).
In this collaboration, Ionis will be responsible for the identification of
antisense drug candidates based on selected targets, while Biogen will be responsible for and pay for non-clinical studies, clinical development, manufacturing, and commercialization.
"We are committed to advancing new RNA-targeted therapeutics, like RNAi and
antisense, to patients with high unmet medical need in China," said Liang Zicai, founder and chairman of Ribo.
Advances in RNAi,
Antisense, and Non-Coding RNA-Based Drugs in Clinical Development
She said that their current findings suggest that the compound, which is called
antisense oligonucleotide (OL-1), is a potential treatment for Alzheimer's disease.
For this purpose, in addition to the investigated wild type tomato, two homozygous independent
antisense transgenic tomato lines (Sl-ERF.B.3.AS42 and Sl-ERF.B.3.AS38) (provided by the Laboratory of Genomic and Fruit Biotechnology, UMR990 INRA/INP-ENSA Toulouse, France) were included in this part of our study.
The collaboration combines Isis'
antisense expertise with Roche's expertise in developing neurodegenerative therapeutics.
Indeed, U7.623
antisense is already confirmed for its effectiveness in repairing gene therapy for several beta-thalassemia mutations [5-8].
Isis Pharmaceuticals, (Nasdaq: ISIS) and its collaborators have presented results on the
antisense inhibition of novel targets that could offer new mechanisms to treat cancer during the American Association for Cancer Research (AACR) meeting.
Research progress in
antisense elements (genetics).